Global Clinical Trials Data

...Because free data should be free

657 studies found for coronavirus
New Search | Refine Search | Download Results

Study Details

Participant Details

Identifiers

Dates

Status
Study
Not yet recruiting
Condition: Pneumonia, Pneumocystis|Coronavirus
Interventions: Darunavir and Cobicistat
Phase: P3
Sponsor: Shanghai Public Health Clinical Center
Collaborators:
Brief Summary / Brief Description: The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of pneumonia caused by the 2019 novel coronavirus
Other IDs: NCT04252274, DACO-nCoV
Study Start: 01/30/2020
Primary Completion: 08/31/2020
First Received: 02/03/2020
Not yet recruiting
Condition: Pneumonia, Pneumocystis|Coronavirus
Interventions: Hydroxychloroquine
Phase: P3
Sponsor: Shanghai Public Health Clinical Center
Collaborators:
Brief Summary / Brief Description: The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of pneumonia caused by the 2019 novel coronavirus
Other IDs: NCT04261517, HC-nCoV
Study Start: 02/06/2020
Primary Completion: 08/31/2020
First Received: 02/07/2020
Not yet recruiting
Condition: Coronavirus Infections|Respiratory Infection Virus
Interventions: methylprednisolone therapy, Standard care
Phase: P2/3
Sponsor: Peking Union Medical College Hospital
Collaborators: Zhongda Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University
Brief Summary / Brief Description: In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for 2019 novel coronavirus (2019-nCoV) patents with Severe acute respiratory failure.
Other IDs: NCT04244591, Glucocorticoid nCoV
Study Start: 01/26/2020
Primary Completion: 04/25/2020
First Received: 01/28/2020
Not yet recruiting
Condition: Cancer|COVID-19
Interventions:
Phase: N/A
Sponsor: Stanford University
Collaborators:
Brief Summary / Brief Description: The purpose of this study is to understand the impact of COVID-19 on patients with cancer through a survey.
Other IDs: NCT04330521, 55596
Study Start: 04/01/2020
Primary Completion: 05/01/2022
First Received: 04/01/2020
Recruiting
Condition: Coronavirus
Interventions: Comprehensive treatment
Phase: N/A
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Collaborators:
Brief Summary / Brief Description: Outbreak of 2019 Novel Coronavirus infection started in Wuhan and quickly spread to the world. Suspected patients were isolated and treated in our department. Clinical data was recorded to investigate the clinical features of patients confirmed and excluded diagnosed of 2019 Novel Coronavirus infection.
Other IDs: NCT04279782, XWX3
Study Start: 01/20/2020
Primary Completion: 01/31/2021
First Received: 02/21/2020
Recruiting
Condition: COVID-19|Liver Cirrhosis
Interventions:
Phase: N/A
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Collaborators: Renmin Hospital of Wuhan University, LanZhou University, Minda Hospital Affiliated to Hubei University for Nationalities, Wuhan Union Hospital, China, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Tianjin Second People's Hospital, Sixth People’s Hospital of Shenyang, Guangxi Zhuang Autonomous Region, Shenzhen Third People's Hospital, Ankang Central Hospital, Xingtai People's Hospital, Dalian Sixth People’s Hospital, The Central Hospital of Lishui City, The Affiliated Third Hospital of Jiangsu University, Suizhou Hospital, Hubei University of Medicine
Brief Summary / Brief Description: COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Other IDs: NCT04329559, CHESS2002
Study Start: 03/30/2020
Primary Completion: 06/29/2020
First Received: 04/01/2020
Recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);
Phase: N/A
Sponsor: The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)
Collaborators:
Brief Summary / Brief Description: Main purpose: To evaluate the efficacy of phosphoric chloroquine for novel coronavirus through clearance time of novel coronavirus. Secondary purpose: 1. To evaluate the efficacy of phosphoric chloroquine for mild/common patients with novel coronavirus(COVID-19) pneumonia through other secondary outcomes; 2. To evaluate the safety of phosphoric chloroquine for patients with novel coronavirus(COVID-19) .
Other IDs: ChiCTR2000030031, N/A
Study Start: 02/20/2020
Primary Completion: 03/20/2021
First Received: 02/20/2020
Recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;
Phase: N/A
Sponsor: The First Affiliated Hospital of Nanchang University
Collaborators:
Brief Summary / Brief Description: The aim was evaluate the effects of novel coronavirus pneumonia rehabilitation plasma in teatment of severe novel coronavirus pneumonia infection.
Other IDs: ChiCTR2000030179, N/A
Study Start: 02/24/2020
Primary Completion: 04/24/2020
First Received: 02/24/2020
Not yet recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);
Phase: N/A
Sponsor: Jingzhou Central Hospital
Collaborators:
Brief Summary / Brief Description: Main purpose: To evaluate the efficacy of phosphoric chloroquine for novel coronavirus through clearance time of novel coronavirus. secondary purpose: 1. To evaluate the efficacy of phosphoric chloroquine for mild/common patients with novel coronavirus(COVID-19) pneumonia through other secondary outcomes; 2. To evaluate the safety of phosphoric chloroquine for patients with novel coronavirus(COVID-19) .
Other IDs: ChiCTR2000029837, N/A
Study Start: 02/17/2020
Primary Completion: 03/17/2020
First Received: 02/17/2020
Recruiting
Condition: Novel Coronavirus Pneumonia (COVID-19)
Interventions: Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;
Phase: N/A
Sponsor: Tongde Hospital of Zhejiang Province
Collaborators:
Brief Summary / Brief Description: 1. Provide effective traditional Chinese medicine treatment protocol for novel coronavirus pneumonia 2. Summarize the characteristics of the TCM syndromes of the novel coronavirus pneumonia 3. Provide effective TCM preparations against novel coronavirus pneumonia
Other IDs: ChiCTR2000030034, N/A
Study Start: 02/01/2020
Primary Completion: 06/30/2020
First Received: 02/01/2020
Studies Shown (1 to 10)